GlassScriptPhysician profile
Nimish B Vakil
NPI 1336124585
$24,934.62
in general payments reported to CMS, 2019-2025
7 companies · $750 in 2025
The $750 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $13.46 · 2021: $4,275 · 2022: $6,872 · 2023: $750 · 2024: $750 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $8,397.42 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $5,603.74 | 2019 | |
| Merck Sharp & Dohme LLC | $5,500.00 | 2019-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $3,252.00 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $2,168.00 | 2019 | |
| Boston Scientific Corporation | $13.46 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nimish Vakil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.